MNG1062
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.499
- MITOTIC_SPINDLE+0.467
- WNT_BETA_CATENIN_SIGNALING+0.386
- TGF_BETA_SIGNALING+0.361
- UV_RESPONSE_DN+0.306
- HEME_METABOLISM+0.264
- NOTCH_SIGNALING+0.245
- ANDROGEN_RESPONSE+0.228
- PI3K_AKT_MTOR_SIGNALING+0.216
- G2M_CHECKPOINT+0.194
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.434
- INFLAMMATORY_RESPONSE-0.361
- INTERFERON_GAMMA_RESPONSE-0.348
- INTERFERON_ALPHA_RESPONSE-0.312
- PANCREAS_BETA_CELLS-0.311
- COAGULATION-0.255
- IL6_JAK_STAT3_SIGNALING-0.246
- MYC_TARGETS_V2-0.231
- TNFA_SIGNALING_VIA_NFKB-0.231
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG502 | — | — | 0.869 |
| 2 | MNG677 | — | — | 0.800 |
| 3 | 589A94F8-2432-4D6D-94EB-B327ECA291AF | — | — | 0.777 |
| 4 | SRR934986 | — | — | 0.776 |
| 5 | BAA2D0D4-DD8C-4F80-8D37-986AFC578536 | — | — | 0.766 |
| 6 | MNG420 | — | — | 0.766 |
| 7 | TCGA-A8-A08O-01A-21R-A056-07 | — | B | 0.765 |
| 8 | MNG335 | — | — | 0.758 |
| 9 | C138638F-C6CB-439B-BFF0-CF097E0B421E | — | — | 0.758 |
| 10 | MNG1056 | — | — | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.499 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.467 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.386 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.361 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.306 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.264 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.245 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.228 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.216 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.194 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.181 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.152 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.135 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.133 | Idelalisib | — uncovered |
| HYPOXIA | 0.113 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.111 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.086 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.073 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.069 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.061 | Temsirolimus | — uncovered |